Cardiovascular Effects of Newly Discovered Peptide Intermedin/adrenomedullin 2
CS Pan,JH Yang,DY Cai,J Zhao,H Gerns,J Yang,JK Chang,CS Tang,YF Qi
DOI: https://doi.org/10.1016/j.peptides.2005.02.013
IF: 3.867
2005-01-01
Peptides
Abstract:Intermedin (IMD) is a novel member of the calcitonin/calcitonin gene-related peptide (CGRP). The present study aimed to investigate the cardiovascular effects of IMDs (IMD1–47 and IMD8–47) in rats. Intravenous administration of 150nmol IMDs continuously decreased mean arterial pressure and inhibited cardiac function. Administration with IMDs decreased left ventricular end-systolic pressure (LVESP) and maximal rate of left-ventricle pressure development (±LVdp/dtmax), and elevated left ventricular end-diastolic pressure (LVEDP). Changes with IMD1–47 treatment were close to that with IMD8–47 (P>0.05). Perfusion of isolated rat hearts in vitro with IMD8–47 (10−8 and 10−7mol/L) resulted in lower LVSP, by 40 and 56% (P<0.01); lower +LVdp/dtmax, by 33 and 47% (P<0.01); lower −LVdp/dtmax, by 25 and 39% (P<0.01); but higher coronary perfusion flow (CPF), by 25% (P<0.05) and 33% (P<0.01), respectively, than controls. However, both IMD8–47 and IMD1–47 (from 10−13 to 10−7mol/L) relaxed preconstricted aortic rings in a dose-dependent manner. Intravenous administration of IMD1–47 and IMD8–47 (10−7mol/L) in vivo increased the cyclic adenosine monophosphate (cAMP) content by 68 and 150% (both P<0.01), respectively, in myocardia and 320 and 281% (both P<0.01), respectively, in aortas, compared with controls. Perfusion of isolated hearts with IMD1–47 and IMD8–47 (10−7mol/L) enhanced cAMP content by 24% (P<0.05) and 73% (P<0.01), respectively, compared with controls. IMDs inhibited 3H-Leucine incorporation in cardiomyocytes in a concentration-dependent manner. IMD1–47 and IMD8–47 (10−7 and 10−8mol/L) decreased 3H-Leucine incorporation by 12–25% (P<0.01) and 14–18% (P<0.01), respectively. IMD mRNA was detected in cultured neonatal cardiomyocytes and isoproterenol-induced hypertrophic myocardia but not normal myocardia of adult rats. These results suggest that IMD might be a regulatory factor for cardiovascular function and myocardial hypertrophy as a cardiovascular active peptide.